144 related articles for article (PubMed ID: 26096682)
1. Effects of enzastaurin and its metabolites on the QT interval in cancer patients.
Welch PA; Ng WT; Darstein CL; Musib L; Lesimple T
J Clin Pharmacol; 2016 Jan; 56(1):101-8. PubMed ID: 26096682
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
3. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
[TBL] [Abstract][Full Text] [Related]
4. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
6. Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants.
Lissy M; Demmel V; Sachse R; Ammer N; Kelepouris N; Ostrow V
Clin Pharmacol Drug Dev; 2021 May; 10(5):494-501. PubMed ID: 32961034
[TBL] [Abstract][Full Text] [Related]
7. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
[TBL] [Abstract][Full Text] [Related]
8. Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting.
Fox GM; Albayaty M; Walker JL; Xue H; Darpo B
Anesth Analg; 2021 Jan; 132(1):150-159. PubMed ID: 31913911
[TBL] [Abstract][Full Text] [Related]
9. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
[TBL] [Abstract][Full Text] [Related]
11. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder.
Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
Clin Ther; 2020 Aug; 42(8):1483-1493.e1. PubMed ID: 32792252
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z; Grasela DM; Krishna G
Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
[TBL] [Abstract][Full Text] [Related]
15. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
Luo WL; Crumley T; Ebel D; Atiee GJ; Royalty J; Johnson-Levonas AO; Wagner J; Lai E
J Clin Pharmacol; 2010 Nov; 50(11):1273-9. PubMed ID: 20107202
[TBL] [Abstract][Full Text] [Related]
16. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
Quinlan M; Zhou J; Hurh E; Sellami D
Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
[TBL] [Abstract][Full Text] [Related]
17. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC Study.
Darpo B; Benson C; Brown R; Dota C; Ferber G; Ferry J; Jarugula V; Keirns J; Ortemann-Renon C; Pham T; Riley S; Sarapa N; Ticktin M; Zareba W; Couderc JP
J Clin Pharmacol; 2020 Jan; 60(1):125-139. PubMed ID: 31378962
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Ogasawara K; Xu C; Yin J; Darpo B; Carayannopoulos L; Xue H; Palmisano M; Krishna G
Clin Pharmacol Drug Dev; 2021 Apr; 10(4):366-375. PubMed ID: 32673446
[TBL] [Abstract][Full Text] [Related]
20. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects.
Spyker DA; Voloshko P; Heyman ER; Cassella JV
J Clin Pharmacol; 2014 Jun; 54(6):665-74. PubMed ID: 24375070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
